Version history

{
  "session_id": "sess_hypdeb_h_58e4635a_20260427_070335",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "content": "\n\n## Expert Assessment: Translational Feasibility of SASP-Complement Hypothesis\n\n### Druggability\n\nThe hypothesis presents **multiple tractable intervention points**, though with varying feasibility. **C1q** is challenging as a target—antibody-based approaches exist (Annexon ANX-009) but require CNS penetration optimization. **C3 inhibition** is more established: Apellis' pegcetacoplan (approved for geographic atrophy) demonstrated that intravitreal C3 modulation is achievable, though CNS delivery remains unsolved. Oral complement inhibitors (Alnylam's cemdisiran for C5) lack meaningful brain exposure. **Senolytic approaches** (dasatinib/quercetin combinations) have shown preliminary safety in aging trials (NCT04785304), but specificity for disease-relevant senescence versus beneficial senescent cells remains unresolved. JAK inhibitors (tofacitinib, baricitinib) could theoretically blunt SASP but would require CNS-penetrant derivatives.\n\n### Competitive Landscape\n\nThis hypothesis enters a **crowded field with fundamental challenges**. Complement therapeutics in neurology have a high attrition history: Alnylam's ALN-CC1 (C1s siRNA) was discontinued despite promising myasthenia gravis data. Roche's RO7121661 (CD40L) failed in MS. The combination angle is novel but unproven—senolytics plus complement inhibition would require two distinct mechanisms, complicating development. Unity Biotechnology's UBX1325 (senolytic) failed in diabetic macular edema despite Phase II entry, raising questions about single-mechanism senolytic efficacy.\n\n### Timeline/Cost Estimates\n\n- Target validation in mouse models: 18-24 months, $1-2M\n- IND-enabling studies: 12-18"
}